Shareholder Report
In 2025 we learned that commercial traction takes time to convert into recognized revenue, but the foundation is solid: invoiced contracts grew +145% YoY and client retention exceeded 90%. In 2026 we are focused on turning that traction into revenue through segment specialization and geographic expansion.
Company Snapshot
€1.3M
2026 Revenue Target
2.15x growth from €604K
27
Team Members
as of H1 2026 close
7
Active Markets
UK target for 2026
FDA
Pre-submission 2026
CE MDR in progress
2025 Close
| Area | Target | Result | |
|---|---|---|---|
| Revenue | €1.44M | €604K (+47% YoY) | Revenue fell short, but commercial focus shifted toward long-term recurring deals |
| Invoiced contracts | n/a | €848K (+145% YoY) | Strongest indicator of commercial traction |
| New markets | 2 | 2 (Poland, Brazil) | 100% |
| ANVISA (Brazil) | Planned | Certified | Enabling commercial operations in Brazil |
| Client retention | n/a | 92% top-half, 83% bottom-half | Retention used as proxy; CSAT not yet measured |
2026 Priorities
- Revenue: Scaling to €1.3M through segment specialization (insurance, public sector, clinical trials). See strategy
- Market expansion: Entering the United Kingdom as priority new market
- Regulatory: Completing CE Mark MDR transition and advancing FDA 510(k) pre-submission
- Customer success: Establishing systematic CSAT measurement (>75% target)
H1 2026 progress
Progress against the four 2026 priorities above, plus other milestones. Shareholders receive the detailed version at each board meeting; this is the summary.
- Revenue (target €1.3M, year weighted to H2 as in 2025): H1 recognized revenue (devengado) was €415K, about 69% of full-year 2025 at the mid-point, with a strong Q2 (€253K, up ~56% on Q1) after a slower Q1. The current internal full-year forecast is ~€878K (+45% YoY), below the €1.3M target; the year is heavily back-loaded and closing the gap depends on converting the advanced pipeline (Sanitas group renewal, AbbVie, Chiesi, J&J Oncoderm) in H2.
- Market expansion (UK): hired Christopher McKee as UK Sales Director to lead entry into the priority new market.
- Regulatory: ENS High (categoría Alta) certification received, unlocking top-tier Spanish public-sector procurement; CE Mark MDR (Class IIb) decision expected before the end of summer; FDA 510(k) pre-submission being finalized for submission before the summer.
- Customer success: systematic CSAT measurement (the gap flagged in 2025) is being set up; first readings still pending.
- Other milestones: "Legit.Health" trademark registered in the US; non-dilutive EPIC-X (EIC, €60K), ICEX Next (€24K) and Fast Track Innobideak (€125K, resolved) secured, with a further ~ €1.5M in grants awaiting resolution (final awards likely lower, as is normal in grants) and two innovation loans (ICO €322K, Elkargi €250K) under analysis; team at 27, hiring deliberately slowed to preserve cash.
- Financing: assembling a ~€2M bridge (blended grants, loans and a convertible note) toward a Series A planned for 2027.
What You'll Find Here
| Section | What's in it |
|---|---|
| Financials | Profit & loss, cash flow, invoice by segment, balance sheet, and funding history |
| Objectives | Goals, results, and strategy for each year (2024, 2025, 2026) |
| Sales | Customers by segment: pharma, insurance, and care providers |
| Team | Org chart, headcount evolution, and cost structure |
| Cap table | Current equity distribution, investors, and ESOP |
| Trajectory & Recognition | Awards, scientific publications, media appearances, and company milestones |
| Shareholder agreement | Full text of the Pacto de Socios |
Last updated
July 2026 (H1 close)
Andy Aguilar | CEO
andy@legit.health | +34 624742302